| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...
 
																	https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid
 
																	Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and pot...
 
																	- Reuters
 
																	Pfizer Inc. (NYSE:PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE:NVO) to acquire Metsera, I...
 
																	Mad Money Lightning Round: Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE...
 
																	Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for ...
 
																	https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...
 
																	DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.